Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

Fig. 1

Imaging of [89Zr]Zr-DFO-Miltuximab® in BALB/c/nude mice. a PET-CT imaging of mice (n = 2) bearing a DU-145 xenograft on day 7 post intravenous injection of [89Zr]Zr-DFO-Miltuximab®. T, tumour; L, liver. b Biodistribution of [89Zr]Zr-DFO-Miltuximab® in BALB/c/nude mouse organs 7 days after injection of [89Zr]Zr-DFO-Miltuximab® (n = 2) by ex vivo analysis of organs by gamma counter. Data are expressed as %injected activity (IA)/gram tissue

Back to article page